← Eichor
Study identifier: NCT06058650 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

Condition: Breast Neoplasm  ·  Sponsor: Mayo Clinic

PhaseNA
Planned participants70
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Mayo Clinic in RochesterRochester, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06058650